The Human Immunodeficiency Virus, short called HIV, targets the human immune system and weakens the surveillance and defense system against infections. Infected people become gradually immunodeficient, while the virus destroys and impairs the function of immune cells. The Immune function is typically measured by the CD4 cell count. The most advanced stage of HIV is the Acquired Immunodeficiency Syndrome (AIDS).
HIV is a major public health issue, since it is the “world’s most leading infectious killer“ (WHO, 2014). Until today, no cure for HIV was found, but treatment with antiretroviral (ARV) drugs can help to control the virus. In a standard antiretroviral therapy (ART) are at least three antiretroviral drugs combatant to suppress the HIV virus and stop the progression of the disease. In 2013 around 12.9 million people are receiving ART globally, of which 11.7 million were in low- and middle-income countries.
Table of Contents
I. Introduction
II. Provisions that regulate the Access to ARVs
The TRIPS Agreement
Compulsory licensing
Voluntary licensing
Parallel importing
TRIPS Plus “TRIPS Plus is going even further than TRIPS” (MSF, 2011).
III. Which provision has been applied? Case study Thailand - granting a compulsory license
IV. Conclusion
Research Objectives and Key Topics
This work examines the impact of the TRIPS Agreement on global access to HIV medication, specifically analyzing how intellectual property protections affect drug affordability. The research investigates whether current trade laws hinder universal access to antiretroviral therapy and explores how developing nations can utilize legal flexibilities to improve public health outcomes.
- The influence of the TRIPS Agreement on pharmaceutical patent rights.
- Mechanisms for improving medicine access, including compulsory and voluntary licensing.
- The implications of "TRIPS Plus" provisions on developing countries.
- Analysis of Thailand's implementation of compulsory licenses for HIV treatment.
- The balance between private patent interests and global public health needs.
Excerpt from the Book
Compulsory licensing
A compulsory license is an authorization granted by the government without the permission of the patent holder. Every country has the right to file a compulsory license either through their own patent law or through the TRIPS Agreement. TRIPS does not set the standards of the grounds or reasons for granting such a license but countries can only use the grounds given by their national legislation. However, TRIPS wants the states to regulate those conditions corresponding to the TRIPS Agreement Article f9 31.
Grounds for compulsory licenses have been specified by countries in many different ways, for example public health reasons, instance emergency situations, epidemics, public non-commercial use, to find a solution for anti-competitive practices or to protect the environment. Since it is a national law decision, which ground is going to be chosen there is a lot of flexibility given.
A compulsory license does not subduct the rights of a patent holder, it simply limits the rights more than before. TRIPS specifies the conditions that need to be applied, once a country wants to grant a compulsory license. An important point is that every case needs to be treated individually. The first step is in general to obtain a license from the patent holder, a voluntary license, on adequate terms. In case of a national emergencies or other circumstances of extreme urgency is no need to file for a voluntary license at first, this is the only instance when the TRIPS Agreement links directly to a compulsory license to save time. Even if a compulsory license is granted through the government the licensees still have to pay a royal fee to the patent holder. Nevertheless, it is to mention that such a few is significantly lower as a voluntary license fee and it still makes medicine more affordable to people than before.
Chapter Summaries
I. Introduction: This chapter introduces the global burden of HIV/AIDS and outlines the study's focus on the TRIPS Agreement, intellectual property rights, and the role of generic medication.
II. Provisions that regulate the Access to ARVs: This chapter details the legal framework of the TRIPS Agreement, explaining mechanisms like compulsory licensing, voluntary licensing, parallel importing, and the restrictive nature of TRIPS Plus provisions.
III. Which provision has been applied? Case study Thailand - granting a compulsory license: This chapter analyzes Thailand's practical application of compulsory licenses to increase access to HIV/AIDS drugs, demonstrating the effectiveness of the strategy despite international pressure.
IV. Conclusion: This chapter synthesizes the findings, arguing that while intellectual property protection is necessary for innovation, it must not supersede the imperative of global public health.
Keywords
TRIPS Agreement, HIV, AIDS, Antiretroviral Drugs, Compulsory Licensing, Intellectual Property, Pharmaceutical Patents, Global Health, Generic Drugs, Voluntary Licensing, Parallel Imports, TRIPS Plus, Public Health, Thailand, Doha Declaration
Frequently Asked Questions
What is the primary focus of this research?
The work investigates the intersection of intellectual property law and global health, specifically how the TRIPS Agreement affects the accessibility and affordability of HIV/AIDS medications in developing countries.
What are the main thematic areas covered?
The core themes include the regulatory framework of TRIPS, the strategies for generic drug production, the socio-economic impact of pharmaceutical patents, and the role of international organizations like the WTO in public health.
What is the central research question?
The paper explores how developing countries can navigate restrictive trade agreements to ensure their populations have access to essential life-saving medicines without violating international property laws.
Which methodology is employed in the work?
The study utilizes a descriptive legal analysis of international trade provisions combined with a qualitative case study of Thailand's policy response to the HIV crisis.
What topics are discussed in the main body?
The main body examines the specific legal provisions of TRIPS, the mechanisms of voluntary vs. compulsory licensing, the threats posed by TRIPS Plus, and the practical challenges of implementing these measures against pharmaceutical lobbying.
Which keywords best describe the paper?
The most relevant keywords include TRIPS Agreement, Compulsory Licensing, HIV/AIDS, Access to Medicine, and Pharmaceutical Patents.
How did Thailand successfully implement its compulsory license strategy?
Thailand moved to issue compulsory licenses for key HIV drugs when price negotiations failed, effectively increasing the number of patients receiving treatment and demonstrating that economic fears regarding trade sanctions were largely overstated.
What is the significance of the "Bolar exemption"?
The Bolar exemption allows generic manufacturers to conduct research and development on patented products before the patent actually expires, which facilitates faster market entry for generic versions once the patent term concludes.
Why are pharmaceutical companies often opposed to compulsory licensing?
Pharmaceutical companies fear that compulsory licensing undermines their monopoly status, reduces their profit margins, and sets precedents that might be used by other nations to bypass high drug costs.
- Arbeit zitieren
- Anonym (Autor:in), 2015, What kind of Provisions regulate the Access to ARV Medicine and how did Thailand react?, München, GRIN Verlag, https://www.grin.com/document/303796
